Protocol Ledger

NCT03549338 · Phase II · TERMINATED

Sym004 Versus Futuximab or Modotuximab in Patients With mCRC

Interventional Phase II clinical trial protocol NCT03549338 sponsored by Symphogen in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-11-29 Enrollment: 2 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03549338
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)2 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03549338
Protocol FieldVerified Registry Value
NCT IdentifierNCT03549338
Consolidated Lead SponsorSymphogen
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment2 participants (ACTUAL)
Registered Start Date2018-11-29
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI